Ohta H, Nemoto K, Nozawa S, Tamura S, Iizuka R
Department of Obstetrics and Gynecology, Tokyo Electric Power Hospital.
Nihon Sanka Fujinka Gakkai Zasshi. 1990 Jul;42(7):675-81.
Danazol, which is commonly employed in the treatment of endometriosis creates a low estrogen and high androgen condition by suppressing ovarian steroidogenesis. When a reproductive-aged woman suddenly develops low estrogen, even if it is reversible, it is possible that it can have some effect on her bone mineral content and there is the danger that this might constitute a risk factor in the development of postmenopausal bone metabolism. In 12 cases of endometriosis (average age 42.2) 400 mg/day Danazol was given for 4 months to determine if a low estrogen and high androgen condition actually continued. The effect on the bone metabolism which provides a background to metacarpal bone mineral content was also examined in comparison with before and after seven months' administration. As a result, after Danazol administration, estradiol showed a tendency to decrease and dehydroepiandrosterone showed a tendency to increase although no significant change in the estrogen and androgen level was recognized. There was also no change on the bone mineral content and there was no significant change in bone metabolism, calcitonin excepted. Therefore, from the results of calcitonin evaluation, 400mg/day Danazol administered for 4 months does not seem to be absorbed by bone and at least appears not to have any significance as a bone metabolism risk factor.
达那唑常用于治疗子宫内膜异位症，它通过抑制卵巢甾体生成来造成低雌激素和高雄激素状态。当一名育龄妇女突然出现低雌激素状态时，即便这种状态是可逆的，它仍可能对其骨矿物质含量产生一定影响，并且存在这种情况可能构成绝经后骨代谢发展的一个危险因素的风险。对12例子宫内膜异位症患者（平均年龄42.2岁）给予每日400毫克达那唑，持续服用4个月，以确定低雌激素和高雄激素状态是否确实持续存在。与给药7个月前后相比，还研究了对作为掌骨矿物质含量背景的骨代谢的影响。结果显示，服用达那唑后，雌二醇呈下降趋势，脱氢表雄酮呈上升趋势，尽管雌激素和雄激素水平未发现显著变化。骨矿物质含量也没有变化，除降钙素外，骨代谢也没有显著变化。因此，从降钙素评估结果来看，每日服用400毫克达那唑4个月似乎不会被骨骼吸收，至少似乎作为骨代谢危险因素没有任何意义。
